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for Myocardial Perfusion Imaging
Is Timing Everything?Vasken Dilsizian, MD,* Jagat Narula, MD, PHDyP ositron emission tomography (PET)–derivednoninvasive quantiﬁcation of hyperemic myo-cardial blood ﬂow and ﬂow reserve in absolute
terms extends the scope of conventional single-
photon emission computed tomography (SPECT)
myocardial perfusion imaging from the detection
of advanced and ﬂow-limiting epicardial coronary
artery disease to the early stages of atherosclerosis
or microvascular dysfunction. Such regional and
global absolute myocardial blood ﬂow determinations
by quantitative PET have identiﬁed coronary event
risk incremental to that provided by severity of coro-
nary artery stenosis.
The high spatial and contrast resolution of the
photon attenuation–free images of PET along with the
superior properties of PET myocardial blood ﬂow
tracers offers several advantages over SPECT. Unlike
SPECT, in which an extrinsic collimator is used to limit
the direction at which photons enter the detector, the
coincidence detection with PET provides intrinsic
collimation and improves the sensitivity of the
camera. As a result, a number of clinical studies with
myocardial perfusion PET have shown an improve-
ment in sensitivity or speciﬁcity for the detection of
coronary artery disease compared with SPECT, with
overall diagnostic accuracy nearly 10% higher with
PET than SPECT. Another important advantage of PET
pertains to its ability to quantify regional myocardial
blood ﬂow in absolute (milliliters per gram perminute)
rather than in relative (percentage radiotracer uptake)From the *University of Maryland School of Medicine, Baltimore,
Maryland; and the yIcahn School of Medicine at Mount Sinai, New York,
New York. The authors have reported that they have no relationships
relevant to the contents of this paper to disclose.terms. Dynamic acquisition of PET radiotracer passing
through the central circulatory system to its extraction
and retention in the left ventricular myocardium
in concert with tracer-kinetic modeling affords the
assessment of regional myocardial blood ﬂow of the
left ventricle at rest and during vasodilator stress in
absolute terms. However, accurate quantiﬁcation of
absolute myocardial blood ﬂow with PET requires that
the timing of the radiotracer injection be optimized to
that of maximal coronary artery vasodilation.
Three U.S. Food and Drug Administration (FDA)–
approved vasodilators are clinically available for
myocardial perfusion studies: adenosine, dipyri-
damole, and regadenoson. Although the physiologic
properties of these commonly used primary coronary
vasodilator drugs are similar, there are noteworthy
differences of each in terms of speciﬁc pharmacology,
mechanism of action, administration, and timing and
duration of maximal coronary artery vasodilation.
Adenosine is a small endogenous compound pro-
duced by the endothelial cells that causes coronary
vasodilation by activating the adenosine 2A (A2A) re-
ceptor. However, because adenosine is an agonist of
all 4 of its receptors (adenosine 1, A2A, adenosine 2B,
and adenosine 3), it may be associated with undesir-
able side effects, such as bronchospasm (adenosine
2B, adenosine 3) and conduction system (adenosine 1)
problems. Dipyridamole is a nucleoside transport in-
hibitor and so increases interstitial ﬂuid adenosine
concentration by blocking its cellular uptake and
subsequent degradation. Thus, dipyridamole serves
as an indirect method for administering adenosine,
and causing coronary vascular smooth muscle dila-
tion. On average, the degree of myocardial hyperemia
with dipyridamole has been found to be com-
parable to that of adenosine but with less consistent
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500subject-to-subject myocardial hyperemic response
than has been observed with adenosine. The more
recently introduced selective A2A receptor agonist
regadenoson has considerably lower afﬁnity for the
other adenosine receptor subtypes, resulting in lesser
frequency of side effects compared with adenosine.
However, the clinical experience with regadenoson
for assessing absolute myocardial blood ﬂow with
PET radiotracers has been lacking in published
research.
In the present issue of iJACC, the results of a paired
comparison of dipyridamole-induced myocardial hy-
peremia with that of regadenoson are reported using
rubidium as the PET myocardial perfusion radiotracer
(1). The investigators observed that hyperemic myo-
cardial blood ﬂow with regadenoson administered
per the manufacturer’s instruction (tracer injection
w10 to 20 s after a 5-ml ﬂush of regadenoson
[0.4 mg/5.0 ml]) was associated with only about 80%
that of dipyridamole-induced hyperemic myocardial
blood ﬂow and ﬂow reserve (142 mg/kg/min over
4 min, with rubidium injection 4 min after the
completion of dipyridamole infusion). However, when
rubidium injection was delayed to 55 s after regade-
noson bolus injection, hyperemic myocardial blood
ﬂow increased to about 90% that of dipyridamole.
These data suggest that accurate quantiﬁcation of
myocardial blood ﬂow is critically dependent on
the interplay between the vasodilator applied and the
timing of the radiotracer injection in relation to the
peak coronary vasodilation achieved by that particular
vasodilator (2).
The more recent FDA approval of the A2A-selective
adenosine receptor agonist regadenoson was on the
basis of a prospective, double-blind, randomized
multicenter phase 3 trial comparing imaging results
in patients undergoing standard gated adenosine
SPECT myocardial perfusion imaging who were ran-
domized in a 2:1 ratio to either regadenoson or
a second adenosine SPECT study using single-photon
emission radiotracers (thallium-201, technetium-99msestamibi or tetrofosmin). PET and positron-emitting
radiotracers (rubidium-82 or nitrogen-13 ammonia)
were not studied, and absolute hyperemic myocar-
dial blood ﬂow or ﬂow reserve was not quantiﬁed in
the randomized trial. Upon receiving FDA approval,
the manufacturer’s recommendation for the optimal
timing of radiotracer delivery after bolus injection of
regadenoson was based on data from intracoronary
ﬂow sensors in animals as well as a small number of
human subjects. Since attaining FDA approval, rega-
denoson has achieved widespread clinical application
with both SPECT and PET technologies, with the
assumption that all vasodilators and myocardial
perfusion tracers are interchangeable (3), regardless
of the instrumentation (SPECT or PET) or data
analysis (qualitative vs. quantitative) applied (4). The
realization that regadenoson underestimates the
peak hyperemia achieved with dipyridamole vasodi-
lator when studied with rubidium PET reported in the
present issue of iJACC (1,2) underscores the impor-
tance of carrying out additional post–FDA approval
studies, particularly if the use of the FDA-approved
vasodilator is expanded beyond the original applica-
tion in the phase 3 clinical trial.
Absolute myocardial blood ﬂow assessment with
pharmacologic vasodilator PET requires in-depth
understanding of the timing and speed with which a
vasodilator is administered in relation to peak
coronary vasodilation and the extraction fraction
of the radiotracer applied at higher ﬂow rates.
Before expanding the clinical application of an
FDA-approved vasodilator with new technologies
and/or radiotracers for quantitative assessment
of myocardial blood ﬂow, it would be prudent to
undertake additional post–FDA approval clinical
investigations.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Jagat Narula, Icahn School of Medicine at Mount
Sinai School, One Gustave L. Levy Place, New York,
New York 10029. E-mail: narula@acc.org.RE F E RENCE S1. Johnson NP, Gould KL. Regadenoson versus
dipyridamole hyperemia for cardiac PET imaging.
J Am Coll Cardiol Img 2015;8:438–47.
2. Sinusas AJ. Does a shortened hyperemia with
regadenoson stress pose a concern for quantitativeRb-82 PET imaging? Optimization of regadenoson
PET imaging. J AmColl Cardiol Img2015;8:448–50.
3. Dilsizian V. Connectivity of radiotracers to va-
sodilators: is thallium the missing link? J Am Coll
Cardiol Img 2009;2:1209–12.4. Dilsizian V, Narula J. Qualitative and quantita-
tive scrutiny by regulatory process: is the truth
subjective or objective? J Am Coll Cardiol Img
2009;2:1037–8.
